Exicure, Inc. Common Stock
$1.23
-$0.12 (-8.89%)
$1.23Day Range$1.40
Key Statistics
Market Cap
$8.05M
Shares Outstanding
6.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 9, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$1.33
Day High
$1.40
Day Low
$1.23
Volume
40.0K
VWAP
$1.27
Prev Close
$1.35
Transactions
--
Acc. Volume
--
About Exicure, Inc. Common Stock
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
PHARMACEUTICAL PREPARATIONSSIC 28348 employees2430 N. HALSTED ST., CHICAGO, IL, 60614847-673-1707IPO May 9, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001698530
- Composite FIGI
- BBG00GTJCSB4
- Share Class FIGI
- BBG00GTJCSC3
- Ticker Root
- XCUR
- SIC Code
- 2834
About Exicure, Inc. Common Stock (XCUR) Stock
Exicure, Inc. Common Stock (XCUR) closed the 2026-09-18 session at $1.23, down 8.89% versus the previous close (-0.12). The stock opened at $1.33 and traded between $1.23 and $1.40 during that session. Session trading volume was 40K shares. The volume-weighted average price (VWAP) is $1.27.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Exicure, Inc. Common Stock has a market capitalization of $8.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. XCUR is listed on the XNAS exchange. The company employs approximately 8 people. Exicure, Inc. Common Stock is headquartered in CHICAGO, IL. The recorded listing date is 2018-05-09.
On this page you can find market XCUR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.